Treatment of Non-small Cell Lung Cancer, Stage IV
- 1 September 2007
- journal article
- practice guideline
- Published by Elsevier BV in Social psychiatry. Sozialpsychiatrie. Psychiatrie sociale
- Vol. 132 (3), 277S-289S
- https://doi.org/10.1378/chest.07-1381
Abstract
No abstract availableThis publication has 74 references indexed in Scilit:
- Adding Gemcitabine to Paclitaxel/Carboplatin Combination Increases Survival in Advanced Non–Small-Cell Lung Cancer: Results of a Phase II-III StudyJournal of Clinical Oncology, 2006
- Phase III Trial of Gemcitabine Plus Carboplatin Versus Single-Agent Gemcitabine in the Treatment of Locally Advanced or Metastatic Non–Small-Cell Lung Cancer: The Swedish Lung Cancer Study GroupJournal of Clinical Oncology, 2005
- Randomized Phase III Study of Matrix Metalloproteinase Inhibitor BMS-275291 in Combination With Paclitaxel and Carboplatin in Advanced Non-Small-Cell Lung Cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR.18Journal of Clinical Oncology, 2005
- Chemotherapy versus supportive care in advanced non-small cell lung cancer: improved survival without detriment to quality of lifeThorax, 2004
- Docetaxel Versus Docetaxel Plus Cisplatin As Front-Line Treatment of Patients With Advanced Non—Small-Cell Lung Cancer: A Randomized, Multicenter Phase III TrialJournal of Clinical Oncology, 2004
- Phase III trial of gemcitabine and carboplatin versus mitomycin, ifosfamide, and cisplatin or mitomycin, vinblastine, and cisplatin in patients with advanced nonsmall cell lung carcinomaCancer, 2003
- Quality of Life (QOL) Assessment of MIP (Mitomycin, Ifosfamide and Cisplatin) Chemotherapy in Advanced Non-small Cell Lung Cancers (NSCLC)Japanese Journal of Clinical Oncology, 1998
- Phase II study of patients with metastatic nonsmall cell carcinoma of the lung treated with paclitaxel by 3-hour infusionCancer, 1997
- Symptom distress in newly diagnosed ambulatory cancer patients and as a predictor of survival in lung cancerJournal of Pain and Symptom Management, 1995
- Influence of extent of disease, histology, and demographic factors on lung cancer survival in the seer population‐based dataSeminars in Surgical Oncology, 1994